Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies
Next-generation cancer drugs targeting cell cycle control beyond current standards move into early human testing across multiple mechanisms.
A comprehensive Trends in Cancer review (MD Anderson/IEO) synthesizes the expanding landscape of CDK-targeted therapies beyond CDK4/6 inhibitors, including CDK2-selective agents, PROTAC degraders, and molecular glues, several of which are now in early clinical trials. This review provides a timely framework for integrating next-generation CDK inhibitors within precision oncology.
What the study was
- Study design
- Narrative review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Trends in Cancer
Why it surfaced
Trends in Cancer; high-quality MDAnderson/IEO authorship; comprehensive emerging CDK inhibitor landscape review; clinically timely.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.